Symbiotec Pharmalab Limited
Open now24–27 Aug 2026
Updated 2026-08-24 (IST)
What Symbiotec Pharmalab Limited does
We are a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms - organic chemistry, biotechnology and complex injectables. We operate as a contract development and manufacturing organisation variably for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms in which we also manufacture our own products.
Symbiotec Pharmalab Limited financials
Rs crore · AnnualLatest year highlighted in green. Sparklines show the trend.
| Fiscal 2024 | Fiscal 2025 | Fiscal 2026 | ||
|---|---|---|---|---|
| Sales | 716 | 752 | 869 | |
| Operating Profit | — | — | — | |
| OPM % | — | — | — | |
| Net Profit | — | — | — | |
| Total Debt | 247 | 541 | 388 |
Symbiotec Pharmalab Limited IPO offer structure
Total: ₹1,757 cr. Fresh issue proceeds go to the company; OFS proceeds go to selling shareholders.
Use of proceeds- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company: ₹113 cr
- General corporate purposes
Symbiotec Pharmalab Limited promoters and holding
- Anil Satwani: Chairman and Managing Director
- Kashish Satwani: President of the human resources department
- Sushil Satwani: Director in the commercial department
- Satwani Holdings LLP: Promoter
Symbiotec Pharmalab Limited strengths and risks
Company-stated strengths and disclosed risk factors from the offer document.
- Global leadership in corticosteroid and steroidal-hormone APIs (p.4)
- Long-standing relationships with domestic and global customer base (p.4)
- Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record (p.4)
- Continuous investment in R&D, with leading technological capabilities among Indian peers (p.5)
- Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings (p.5)
- We derive almost all of our revenue from the sale of APIs, and any reduction in demand or disruption in production could adversely affect us. (p.10)
- Our manufacturing facilities are subject to periodic inspections and audits, and any failures may subject us to regulatory action. (p.10)
- We export our products to various countries, and our inability to handle risks associated with export sales could adversely affect us. (p.10)
- Revenue from the United States is significant, and the imposition of tariffs or anti-outsourcing legislation could adversely affect us. (p.11)
- We derive a substantial portion of our revenue from certain key customers, and loss of relationship with them could affect us. (p.11)
Symbiotec Pharmalab Limited market and competition
The company claims global leadership in corticosteroid and steroidal-hormone APIs.
Symbiotec Pharmalab Limited outlook, as the document states it
The company plans to build on its global leadership by expanding its product portfolio across steroidal-hormones in its own API and ingredients business. It also aims to build on fermentation capabilities and expand biotechnology offerings such as GLP-1 and Insulin, and commercialize complex injectables through differentiated drug device combinations.
Never miss an IPO like this
Every upcoming IPO analysed: subscription, GMP and a DRHP breakdown, in your inbox, free. One email when each one opens.
Symbiotec Pharmalab Limited IPO: common questions
When does the Symbiotec Pharmalab Limited IPO open and close?
The Symbiotec Pharmalab Limited IPO is open from 24 Aug 2026 to 27 Aug 2026.
What is the Symbiotec Pharmalab Limited IPO price band?
The price band is ₹938–₹988 per share.
What is the lot size and minimum investment for the Symbiotec Pharmalab Limited IPO?
One lot is 15 shares, and a retail application must be at least one lot. That is about ₹14,820 at the upper end of the band. An HNI application starts above Rs 2 lakh, so the minimum is higher for that category.
What is the grey-market premium (GMP) for the Symbiotec Pharmalab Limited IPO?
As of 24 Aug 2026 the indicative GMP is +38.5%. GMP is unregulated and self-reported. Never decide on it alone.
When are the Symbiotec Pharmalab Limited IPO allotment and listing dates?
Not published yet. Derived from the close date on the usual timetable: allotment around 28 Aug 2026, refund/unblock around 31 Aug 2026 and listing around 1 Sep 2026. Treat these as estimates until the exchange confirms them.
How do I apply for the Symbiotec Pharmalab Limited IPO?
Through any broker app or your bank's net banking, using a demat account and a PAN. You bid in lots at a price inside the band, or at cut-off. The money is blocked in your account, not debited, until allotment. One application per PAN. We do not recommend brokers and carry no broker links. How to apply, start to finish →
Sources & method
Subscription and issue data come from the NSE and BSE exchange feeds, with the third-party aggregator, clearly labelled, where an exchange feed is unreachable. DRHP analysis is extracted from the offer document itself, every figure cited to its page. Each figure on the page carries its source and its timestamp.
Grey-market premium (GMP) is unregulated.
Every GMP figure is a self-reported grey-market estimate. No exchange, regulator or clearing body records or audits it, and there is no settlement guarantee or recourse. Shown for context only; never decide on GMP alone. New to GMP? The 30-second explainer →
How often do these actually open above the issue price?
Of the 351 mainboard IPOs that have listed on the NSE since 2021, 254 (72%) opened above their issue price, at a median of +10%. That is the segment's own record, not a forecast for this issue.